MedPath

Micafungin

Generic Name
Micafungin
Brand Names
Mycamine
Drug Type
Small Molecule
Chemical Formula
C56H71N9O23S
CAS Number
235114-32-6
Unique Ingredient Identifier
R10H71BSWG
Background

Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.

Indication

Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.

Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Associated Conditions
Abscesses, Aspergillosis, Candidemia, Candidiasis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Acute disseminated Candidiasis

Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection

Phase 4
Completed
Conditions
Neonatal Infection
Invasive Fungal Infections
Interventions
First Posted Date
2024-05-14
Last Posted Date
2024-05-16
Lead Sponsor
Ain Shams University
Target Recruit Count
56
Registration Number
NCT06413056
Locations
🇪🇬

Ain Shams University Hospitals, Cairo, Abbassia, Egypt

Antimicrobial Revision in Persistent Febrile Neutropenia

Phase 4
Recruiting
Conditions
Febrile Neutropenia
Interventions
First Posted Date
2023-03-27
Last Posted Date
2024-05-16
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
120
Registration Number
NCT05784844
Locations
🇺🇸

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Evaluate Bioequivalence of Micafungin (50mg/Vial)

Phase 4
Completed
Conditions
Invasive Candidiasis
Interventions
First Posted Date
2022-08-11
Last Posted Date
2022-08-11
Lead Sponsor
Yung Shin Pharm. Ind. Co., Ltd.
Target Recruit Count
14
Registration Number
NCT05496725
Locations
🇨🇳

Taichung Veterans General Hospital, Taichung, Taiwan

Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors

Phase 4
Conditions
Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease
Interventions
First Posted Date
2021-02-04
Last Posted Date
2021-02-04
Lead Sponsor
Shandong Provincial Hospital
Target Recruit Count
230
Registration Number
NCT04738955
Locations
🇨🇳

Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China

To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation

Phase 4
Not yet recruiting
Conditions
Liver Transplantation
Interventions
First Posted Date
2021-01-28
Last Posted Date
2022-08-16
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
200
Registration Number
NCT04728971

Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin

Phase 4
Terminated
Conditions
Invasive Candidiasis
Interventions
Diagnostic Test: 1,3-β-D-glucan quantification
First Posted Date
2019-04-08
Last Posted Date
2021-04-12
Lead Sponsor
Fadoi Foundation, Italy
Target Recruit Count
14
Registration Number
NCT03906916
Locations
🇮🇹

Ente Ospedaliero Galliera, Genova, Italy

🇮🇹

Ospedale "Antonio Cardarelli, Napoli, Italy

🇮🇹

Ospedale "S. Anna", Como, Italy

and more 16 locations

Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis

Phase 2
Completed
Conditions
Candidiasis, Systemic
Candida Meningitis
Interventions
First Posted Date
2018-02-05
Last Posted Date
2024-11-18
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
35
Registration Number
NCT03421002
Locations
🇮🇹

Site IT39002, Rome, Italy

🇮🇹

Site IT39001, Rome, Italy

Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study

Completed
Conditions
Invasive Fungal Infections
Interventions
First Posted Date
2017-06-02
Last Posted Date
2024-10-21
Lead Sponsor
Astellas Pharma Singapore Pte. Ltd.
Target Recruit Count
120
Registration Number
NCT03174457
Locations
🇨🇳

Site TW601, Taipei, Taiwan

🇨🇳

Site TW604, Taipei, Taiwan

🇰🇷

Site KR401, Seoul, Korea, Republic of

and more 13 locations

Micafungin Pharmacokinetics in Obese Patients

Phase 4
Completed
Conditions
Morbid Obesity
Interventions
First Posted Date
2017-04-06
Last Posted Date
2020-10-19
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
24
Registration Number
NCT03102658
Locations
🇳🇱

St Antoniusziekenhuis, Nieuwegein, Netherlands

🇳🇱

Radboudumc CRCN, Nijmegen, Netherlands

A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections

Completed
Conditions
Invasive Fungal Infections
Interventions
First Posted Date
2016-02-10
Last Posted Date
2016-02-10
Lead Sponsor
Astellas Pharma China, Inc.
Target Recruit Count
2555
Registration Number
NCT02678598
© Copyright 2025. All Rights Reserved by MedPath